120 Initial investigations into the neuroprotective effects of GLP-1RAs were conducted in diabetic animal models, where subcutaneous administration of liraglutide not only ameliorated hyperglycemia and peripheral insulin resistance, but also restored impaired brain insulin signaling, resulting in reduced tau hyperphosphorylation associated with AD pathology
Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, Khalid M
A study extension also found that people with a starting BMI of 35 or above who continued treatment to 104 weeks lost up to an average of 30.3% of their body weight
Compounded tirzepatide produces greater average weight loss than semaglutide, which sounds appealing from a fat loss perspective
Those facing challenges losing weight through diet and exercise alone Patients who are at risk of developing diabetes due to weight and other health factors As with all medications, GLP-1 prescriptions are based on a thorough assessment by healthcare professionals
+++ represent significance compared to other positive drug (++)
